HER2+ metastatic breast cancer: first-line reasoning

Learning objectives

1. Identify the HER2-IHC/FISH workup, organ-function baseline, and ER/PR co-status needed before HER2+ metastatic first-line treatment selection.
2. Explain why docetaxel + trastuzumab + pertuzumab (THP) remains the standard first-line backbone in the OpenOnco model and where T-DXd, T-DM1, and tucatinib fit downstream.
3. Recognize parallel obligations — baseline LVEF, brain MRI when CNS symptoms are present, and germline BRCA testing — that do not change the first-line regimen but change the safety plan.

At a glance

• HER2 amplification confirmed by IHC 3+ or ISH-positive is required before the first-line plan; the HER2-low band still belongs in the HR+ chapter.
• Docetaxel + trastuzumab + pertuzumab (THP) is the standard first-line backbone; trastuzumab + pertuzumab maintenance continues after chemotherapy completion.
• Trastuzumab deruxtecan (T-DXd) is modeled as the canonical 2L option after THP progression (DESTINY-Breast03).
• Active CNS metastases and germline BRCA status are parallel obligations that do not shift the 1L backbone but bring tucatinib- and PARP-inhibitor reasoning into the longer arc.
• This chapter is an OpenOnco-authored learning aid, not official ESMO content or a CME-credit activity.

Diagnostic minimum

HER2-positive metastatic breast cancer is defined by IHC 3+ or in-situ hybridization-positive HER2 amplification on the metastatic lesion or, when not feasible, on the primary tumor with a clear discussion of discordance risk. Before the first-line plan the chapter expects confirmed HER2 amplification, ER/PR co-status (because endocrine therapy joins the conversation after THP completion), baseline LVEF and ECG before any HER2-directed antibody, germline BRCA1/2 testing, and brain imaging when CNS symptoms are present even though the regimen does not change for asymptomatic CNS disease.

Linked entities

Section sources

• SRC-NCCN-BREAST-2025 NCCN Clinical Practice Guidelines — Breast Cancer
• SRC-ESMO-BREAST-METASTATIC-2024 ESMO Clinical Practice Guideline on Metastatic Breast Cancer

First-line decision logic

OpenOnco models the first-line decision as docetaxel + trastuzumab + pertuzumab (THP) for HER2-amplified metastatic disease, with trastuzumab + pertuzumab maintenance continuing after taxane completion (CLEOPATRA). HR co-positive disease adds endocrine therapy to the maintenance phase rather than replacing the HER2-directed backbone. Frailty, organ dysfunction, or cardiac contraindications are evaluated against THP before any de-intensification choice, and active visceral crisis remains a separate emergency pathway.

Linked entities

Section sources

• SRC-CLEOPATRA-SWAIN-2015 Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
• SRC-NCCN-BREAST-2025 NCCN Clinical Practice Guidelines — Breast Cancer

Second-line and CNS-aware sequencing

After progression on THP the canonical 2L option in the OpenOnco model is trastuzumab deruxtecan (DESTINY-Breast03). Patients with active CNS metastases — particularly progression after IO/HER2-directed therapy — pull tucatinib + trastuzumab + capecitabine into the conversation because the HER2CLIMB trial demonstrated CNS activity. Germline BRCA1/2 status brings PARP-inhibitor reasoning into the longer sequencing arc but does not displace the HER2-directed backbone at any line.

Linked entities

Section sources

• SRC-DESTINY-BREAST03-CORTES-2022 Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
• SRC-HER2CLIMB-MURTHY-2019 Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
• SRC-OLYMPIAD-ROBSON-2017 Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

Common traps

Do not treat regimen selection as the whole task. LVEF surveillance is required throughout HER2-directed therapy, not only at baseline; pregnancy and contraception planning are required for premenopausal patients because anti-HER2 antibodies are teratogenic; CNS imaging on symptom rather than schedule remains the OpenOnco default unless a HER2CLIMB-driven question changes the cadence; and HER2 status should be re-biopsied at progression because discordance between primary and metastatic samples is well-described. None of these change the 1L THP call by themselves, but missing them changes the safety plan.

Linked entities

Section sources

• SRC-NCCN-BREAST-2025 NCCN Clinical Practice Guidelines — Breast Cancer
• SRC-ESMO-BREAST-METASTATIC-2024 ESMO Clinical Practice Guideline on Metastatic Breast Cancer

Worked synthetic cases

• patient_breast_her2_pos_met_1l_thp HER2+ 1L on docetaxel + trastuzumab + pertuzumab - standard-track reasoning, LVEF and ECG baseline examples/patient_breast_her2_pos_met_1l_thp.json
• patient_breast_her2_pos_met_2l_tdxd HER2+ post-THP: T-DXd at 2L - DESTINY-Breast03 sequencing examples/patient_breast_her2_pos_met_2l_tdxd.json
• patient_breast_her2_pos_2l_brain_mets_tucatinib HER2+ with active brain mets: tucatinib triplet - CNS-aware sequencing, HER2CLIMB context examples/patient_breast_her2_pos_2l_brain_mets_tucatinib.json